Neuropsychiatric Research Institute, Fargo, North Dakota
15
0
0
10
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 55/100
20.0%
3 terminated/withdrawn out of 15 trials
76.9%
-9.6% vs industry average
53%
8 trials in Phase 3/4
20%
2 of 10 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (15)
Integrative Cognitive-Affective Therapy for Binge Eating Disorder
Role: collaborator
Psychosocial Issues and Bariatric Surgery
Role: lead
Mechanistic Investigation Of Intestinal Cytochrome p450 3A4 Following Roux-en-Y Surgery And Its Effect on Plasma Concentrations of Buspirone
Role: collaborator
Pharmacokinetics of Lisdexamfetamine (Vyvanse®) in Post-bariatric Surgery Patients
Role: collaborator
The Effect of Nutrient Intake on the Microbiome, Weight, and Glucoregulation (NI-MWG)
Role: collaborator
Testing an Alternative Therapy for Bulimia Nervosa
Role: lead
Cognitive Effects of Bariatric Surgery
Role: collaborator
Alcohol Related Impairment and Reinforcement: Pre to Post Roux en Y Gastric Bypass Surgery
Role: lead
A Comparison of Sustained and Extended Release Bupropion Following Bariatric Surgery
Role: collaborator
Venlafaxine PK Following Bariatric Surgery
Role: collaborator
Topiramate Augmentation in Bulimia Nervosa Partial Responders
Role: lead
Effects of Gastric Bypass on Blood Levels of Duloxetine
Role: lead
A Preliminary Comparison of the Blood Levels of Medications in Obese Subjects Compared to Post-Gastric Bypass Subjects
Role: lead
Pramipexole for Binge Eating Disorder
Role: lead
Effects of Modafinil on Olanzapine Weight Gain
Role: lead
All 15 trials loaded